DNA topoisomerase II as a target for cancer chemotherapy. (Q34718447)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

review article

1 reference

title

DNA topoisomerase II as a target for cancer chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

Jerrylaine V Walker

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

570-589

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Topoisomerase II and the response to antileukemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Clinical resistance to topoisomerase-targeted drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA topoisomerase II is required at the time of mitosis in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Eukaryotic DNA topoisomerase II beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Topoisomerase II: A specific marker for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA topoisomerase IIbeta and neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Azatoxin Is a Mechanistic Hybrid of the Topoisomerase II-Targeted Anticancer Drugs Etoposide and Ellipticine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Structure and mechanism of DNA topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase II beta from Chinese hamster lung cells sensitive and resistant 9-OH-ellipticine

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

XK469, a selective topoisomerase IIbeta poison

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Processing of topoisomerase I cleavable complexes into DNA damage by transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Antitopoisomerase drug action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Ten-day schedule oral etoposide therapy in advanced childhood malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

From amplification to function: the case of the MDR1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Drug resistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

A family of drug transporters: the multidrug resistance-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

The molecular biology of the CCAAT-binding factor NF-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

p53 regulates the minimal promoter of the human topoisomerase IIalpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Using yeast to study resistance to topoisomerase II-targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Energy coupling in DNA gyrase and the mechanism of action of novobiocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

21 January 2018

Dexrazoxane (ICRF-187).

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Phase II trial of merbarone in patients with malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Myeloid neoplasia in children treated for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Two different classes of therapy-related and de-novo acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

In vitro evolution of preferred topoisomerase II DNA cleavage sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Metabolites of daidzein and genistein and their biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Apurinic sites are position-specific topoisomerase II poisons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002156

21 January 2018

Identifiers

DOI

10.1081/CNV-120002156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094551%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference